Literature DB >> 6205881

Antigen-specific proliferative human T cell clones with specificity for diphtheria toxoid: genetic and molecular restriction by class II antigens.

F Triebel, V Missenard-Leblond, B Autran, M C Couty, D Charron, P Debré.   

Abstract

Human T lymphocyte clones (TLC) specific for diphtheria toxoid (DT) were isolated from a DR6/7 individual by cloning in soft agar in vivo sensitized T lymphocytes. We report here the isolation and characterization of 3 of these clones by studying: (a) the kinetic of activation, (b) the surface phenotypes, (c) the fine specificity for one of the 2 DT chains and (d) the genetic restriction of the proliferative response by the haplotype DR7. Moreover, blocking studies of the proliferative response to DT by various immunochemically characterized anti-HLA-DR monoclonal antibodies indicate that, on the DR7 molecule, more than one Ia determinant may participate in the clonal DT proliferative response. By using human TLC of a defined specificity and well-characterized anti-DR monoclonal antibodies, such studies may help to define the functional repertoire of Ia molecules in man.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6205881     DOI: 10.1002/eji.1830140805

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  3 in total

1.  Modulation of the HLA class II antigen at a molecular level by maternal serum among cord blood cells and unrelated lymphocytes.

Authors:  Y E Vanderbeeken; J Duchateau; H Colle; M Gregoire; P Desseilles; A Lucas
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

2.  The intracellular Ca2+ concentration optimal for T cell activation is quite different after ionomycin or CD3 stimulation.

Authors:  E Donnadieu; G Bismuth; A Trautmann
Journal:  Pflugers Arch       Date:  1995-02       Impact factor: 3.657

3.  Human immunodeficiency virus-1 glycoproteins gp120 and gp160 specifically inhibit the CD3/T cell-antigen receptor phosphoinositide transduction pathway.

Authors:  D Cefai; P Debre; M Kaczorek; T Idziorek; B Autran; G Bismuth
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.